I3 Health Podcaster

Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as add…

Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health’s CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented…

In recent years, numerous developments have occurred in metastatic castration-resistant prostate cancer (CRPC) treatment and management. Last year, Kathleen Burns, MSN, NP, Nurse Practitioner in the Division of Genitourinary Medical Oncology at City of Hope Comprehensive Cancer Center, recorded an activity with i3 Health titled Overcoming Nursing M…

Click here to view and claim credit for Managing Toxicities of Novel Breast Cancer Therapies: PI3K Inhibitors, an accredited CME/NCPD/CPE activity by i3 Health: https://i3health.com/odabc-pi3k.Phosphatidylinositol-3-kinase (PI3K) inhibitors are effective treatment for patients with breast cancer but can be associated with significant hyperglycemia …

Click here to claim CME/NCPD credit for this activity: i3health.com/oda-gvhdThis audio includes both the additional updates interview and complete podcast from i3 Health’s CME/NCPD activity New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease.First, listen along as Dr. Shernan Holtan shares the latest data from the BTM CTN 1…

In 2022, Dr. Maura Abbott, Associate Professor of Nursing at the Columbia University School of Nursing, served as faculty for i3 Health’s CME/NCPD approved activity, New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia. Now, in this follow-up interview with Oncology Data Advisor, Dr. Abbott reinforces the importance of educati…

Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With nu…

In 2022, Dr. Shernan Holtan, Associate Professor at the University of Minnesota Medical School, recorded a CME/NCPD activity centered on new therapeutic avenues for improved patient outcomes in graft-versus-host-disease (GVHD). Recently, at the American Society of Hematology (ASH) Annual Meeting, she presented results of the BMT CTN 1703 trial, whi…

Click here to view and claim credit for Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer, an accredited CME/NCPD activity provided by i3 Health: i3health.com/nsclc-immunotherapyJust under a year ago, Beth Sandy, MSN, CRNP, a Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Cente…

This 2-module continuing pharmacy education—(CPE) Strategy Session brings together 2 expert pharmacists to discuss treatment goals and value-based care for patients with newly diagnosed multiple myeloma. Learners must complete both modules to receive credit.In Module 1 of this CPE-approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncolog…

In 2022, Allison Imahiyerobo, an Advanced Practice Nurse at the Englewood Health Physician Network in New Jersey, led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity with i3 Health, New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia. A year later, Ms. Imahiyero…

In 2022, Dr. Maura Abbott, Associate Professor of Nursing at the Columbia University School of Nursing, served as faculty for i3 Health’s CME/NCPD approved activity, New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia. Now, in this follow-up interview with Oncology Data Advisor, Dr. Abbott reinforces the importance of educati…

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibr…

In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School, served as faculty for Therapy of B-Cell Acute Lymphoblastic Leukemia (ALL): an Evolving Landscape, presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were p…

Visit i3health.com/relapsed-refractory-multiple-myeloma to book a live or virtual meeting at your own institution and hear more expert perspectives from Dr. Kumar or other esteemed multiple myeloma faculty!Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Seque…

In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down …

Since the original activity, Treatment Advances in Waldenstrom Macroglobulinemia, was originally presented and recorded, there have been several significant updates in the treatment and management of WM.Dr. Gertz recently sat down with Oncology Data Advisor again to discuss these updates and share all that has occurred in this evolving field. Don't…